Search Results - "EIERMANN, W" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

by Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.
Published in Annals of oncology (01.11.2020)

Get full text

Journal Article

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

by Denkert, C., Loibl, S., Müller, B.M., Eidtmann, H., Schmitt, W.D., Eiermann, W., Gerber, B., Tesch, H., Hilfrich, J., Huober, J., Fehm, T., Barinoff, J., Jackisch, C., Prinzler, J., Rüdiger, T., Erbstößer, E., Blohmer, J.U., Budczies, J., Mehta, K.M., von Minckwitz, G.
Published in Annals of oncology (01.11.2013)

Get full text

Journal Article

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

by Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., Balic, M., Eidtmann, H., Eiermann, W., Steger, G., Kwasny, W., Dubsky, P., Selim, U., Fitzal, F., Hochreiner, G., Wette, V., Sevelda, P., Ploner, F., Bartsch, R., Fesl, C., Greil, R.
Published in Annals of oncology (01.02.2015)

Get full text

Journal Article

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

by Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.
Published in Annals of oncology (01.09.2018)

Get full text

Journal Article

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

by Kaufmann, M., von Minckwitz, G., Bear, H.D., Buzdar, A., McGale, P., Bonnefoi, H., Colleoni, M., Denkert, C., Eiermann, W., Jackesz, R., Makris, A., Miller, W., Pierga, J.-Y., Semiglazov, V., Schneeweiss, A., Souchon, R., Stearns, V., Untch, M., Loibl, S.
Published in Annals of oncology (01.12.2007)

Get full text

Journal Article

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer : Pivotal trial data

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer : Pivotal trial data

by EIERMANN, W
Published in Annals of oncology (2001)

Get full text

Conference Proceeding Journal Article

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

by Ellis, Matthew J., Tao, Yu, Luo, Jingqin, A'Hern, Roger, Evans, Dean B., Bhatnagar, Ajay S., Chaudri Ross, Hilary A., von Kameke, Alexander, Miller, William R., Smith, Ian, Eiermann, Wolfgang, Dowsett, Mitch
Published in JNCI : Journal of the National Cancer Institute (01.10.2008)

Get full text

Journal Article

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

by Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., Blohmer, J.
Published in Annals of oncology (01.03.2013)

Get full text

Journal Article

A pooled analysis of studies evaluating the impact of multi-gene assay testing on adjuvant treatment decisions for women with node-positive breast cancer

A pooled analysis of studies evaluating the impact of multi-gene assay testing on adjuvant treatment decisions for women with node-positive breast cancer

by Braybrooke, J, Eiermann, W
Published in Breast (Edinburgh) (01.03.2017)

Get full text

Journal Article

Locoregional treatments for triple-negative breast cancer

Locoregional treatments for triple-negative breast cancer

by Eiermann, W, Vallis, K A
Published in Annals of oncology (01.08.2012)

Get full text

Journal Article

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

by Mackey, J.R., Pieńkowski, T., Crown, J., Sadeghi, S., Martin, M., Chan, A., Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M.F., Sauter, G., Lindsay, M., Houé, V., Buyse, M., Drevot, P., Hitier, S., Bensfia, S., Eiermann, W.
Published in Annals of oncology (01.06.2016)

Get full text

Journal Article

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

by Pegram, Mark D., Pienkowski, Tadeusz, Northfelt, Donald W., Eiermann, Wolfgang, Patel, Ravi, Fumoleau, Pierre, Quan, Eleonor, Crown, John, Toppmeyer, Deborah, Smylie, Michael, Riva, Alessandro, Blitz, Sandra, Press, Michael F., Reese, David, Lindsay, Mary-Ann, Slamon, Dennis J.
Published in JNCI : Journal of the National Cancer Institute (19.05.2004)

Get full text

Journal Article

Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study

Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study

by JONAT, W, KAUFMANN, M, EIERMANN, W, SZAKOLCZAI, I, PALMER, M, SCHUMACHER, M, GEBERTH, M, LISBOA, B, SAUERBREI, W, BLARNEY, R, CUZICK, J, NAMER, M, FOGELMAN, I, DE HAES, J. C, DE MATTEIS, A, STEWART, A
Published in Journal of clinical oncology (15.12.2002)

Get full text

Journal Article

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

by Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudri-Ross, H. A., Dugan, M., Borgs, M., Semiglazov, V.
Published in Annals of oncology (01.11.2001)

Get full text

Journal Article

Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

by von Minckwitz, G., Kümmel, S., du Bois, A., Eiermann, W., Eidtmann, H., Gerber, B., Hilfrich, J., Huober, J., Costa, S. D., Jackisch, C., Grasshoff, S.-T., Vescia, S., Skacel, T., Loibl, S., Mehta, K. M., Kaufmann, M.
Published in Annals of oncology (01.02.2008)

Get full text

Journal Article

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

by Gonçalves, A., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Yerushalmi, R., Martín, M., Al-Adhami, M., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment

by Martín, M., Eiermann, W., Rugo, H.S., Ettl, J., Hurvitz, S.A., Gonçalves, A., Yerushalmi, R., Markova, D., Tudor, I.C., Blum, J.L., Hannah, A.L., Litton, J.K.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Statistical controversies in clinical research: statistical significance—too much of a good thing

Statistical controversies in clinical research: statistical significance—too much of a good thing

by Buyse, M., Hurvitz, S.A., Andre, F., Jiang, Z., Burris, H.A., Toi, M., Eiermann, W., Lindsay, M.-A., Slamon, D.
Published in Annals of oncology (01.05.2016)

Get full text

Journal Article

$Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer$

Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer

by Schmidt, M., Rüttinger, D., Sebastian, M., Hanusch, C.A., Marschner, N., Baeuerle, P.A., Wolf, A., Göppel, G., Oruzio, D., Schlimok, G., Steger, G.G., Wolf, C., Eiermann, W., Lang, A., Schuler, M.
Published in Annals of oncology (01.09.2012)

Get full text

Journal Article

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study

by Semiglazov, V, Eiermann, W, Zambetti, M, Manikhas, A, Bozhok, A, Lluch, A, Tjulandin, S, Sabadell, M.D, Caballero, A, Valagussa, P, Baselga, J, Gianni, L
Published in European journal of surgical oncology (01.10.2011)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[15]